Market Place
Sourcing Support
FDA Accepts Deciphera`s NDA For Vimseltinib For TGCT Treatment Under Review
15 Aug 2024 //
BUSINESSWIRE
EMA Accepts Deciphera`s MAA For Vimseltinib In TGCT
18 Jul 2024 //
BUSINESSWIRE
Deciphera`s MOTION Data, Vimseltinib In TGCT In The Lancet, At ASCO
03 Jun 2024 //
BUSINESSWIRE
Deciphera`s tumor-tackling oral med achieves 40% response rate
31 Oct 2023 //
FIERCE BIOTECH
Deciphera Announces Positive Results from Phase 3 Study of Vimseltinib
30 Oct 2023 //
BUSINESSWIRE
Deciphera Announces Completion of Enrollment for PIII Study of Vimseltinib
01 Mar 2023 //
BUSINESSWIRE
Deciphera Presents Updated Phase 1/2 Data for Vimseltinib in TGCT
11 Sep 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.